Glycopyrronium bromide/formoterol
Combination of
Glycopyrronium bromideMuscarinic anticholinergic
FormoterolLong-acting β2 agonist (LABA)
Clinical data
Trade namesBevespi Aerosphere
License data
Routes of
By mouth (inhalation)
ATC code
Legal status
Legal status

Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[2][3] It is a combination of glycopyrronium bromide and formoterol. It is inhaled.[2][3]

The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness.[3]

Glycopyrronium bromide is a muscarinic receptor antagonist.[3] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.[3] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.[3]

Formoterol is a long-acting beta-2 agonist.[3] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways.[3] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.[3]

Medical uses

Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).[3]


Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016,[4] and in the European Union in December 2018.[3]

It is marketed by AstraZeneca.[2][3]


  1. ^ "Search Page - Drug and Health Product Register". 23 October 2014.
  2. ^ a b c d "Bevespi Aerosphere- glycopyrrolate and formoterol fumarate aerosol, metered". DailyMed. 29 May 2019. Retrieved 8 May 2020.
  3. ^ a b c d e f g h i j k l m "Bevespi Aerosphere EPAR". European Medicines Agency (EMA). 18 October 2018. Retrieved 8 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol". U.S. Food and Drug Administration (FDA). 16 February 2018. Retrieved 8 May 2020.

Further reading